Navigation Links
Cell Therapeutics Decreases Net Loss for Nine Month Period in 2009 Compared to Same Period in 2008 by 45%
Date:11/5/2009

----- Operating expenses, net: Cost of product sold - 692 - 2,349 Research and development 7,602 11,326 22,878 43,038 Selling, general and administrative 19,667 7,834 38,997 30,562 Amortization of purchased intangibles - 606 - 1,540 Restructuring charges and related gain on sale of assets, net (178) - 3,766 - Gain on sale of investment in joint venture - - (10,244) - --- --- ------- --- Total operating expenses, net 27,091 20,458 55,397 77,489 ------ ------ ------ ------ Loss from operations (27,071) (17,858) (55,337) (68,605) Other income (expense): Investment and other income, net 26 146 97 499 Interest expense (826) (2,575) (4,026) (6,955) Amortization of debt discount and issuance costs (227) (11,113) (5,575) (52,259) Foreign exchange gain 183 3,070 278 909 Make-whole interest expense - (19,135) (6,345) (52,512) Gain on derivative liabilities, net - 12,915 7,218 56,092 Gain (loss) on exchange of convertible notes 180 (10,272) 7,381 (15,880) Equity loss from investment in joint venture - - (1,204) - Milestone modification expense (6,000) - (6,000) - Settlement expense, net (1,342) (799) (4,710)
'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Prime Therapeutics Receives TIPPS Certification
2. Adams Respiratory Therapeutics to Celebrate 10th Anniversary of its Incorporation on September 12
3. Transition Therapeutics Announces Fiscal 2007 Year End Financial Results
4. Lorus Therapeutics announces election of three new Directors and appoints a new Chairman
5. Deane F. Johnson Center for Neurotherapeutics to Launch First Mobile Medical Unit on October 4th
6. Russell Investment Group Advises Protalix Biotherapeutics of Index Adjustment
7. Adams Respiratory Therapeutics Announces FDA Approval of Grape-Flavored Delsym(R)
8. Prime Therapeutics Announces URAC Accreditation
9. Cell Therapeutics, Inc. (CTI) to Present at BIO Investor Forum
10. Horizon Therapeutics, Inc. Scheduled to Present at Upcoming BioPartnering Europe Meeting
11. Sontra Medical Corporation Changes Name to Echo Therapeutics, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... NY (PRWEB) September 22, 2014 ... whom all of the federal mesh lawsuits ( ... Corp. have been consolidated for pretrial matters, issued ... Scientific Corp. Pelvic Repair System Products Liability Litigation ... of West Virginia; Case no. 2:12-md-02326)—requiring that four ...
(Date:9/22/2014)... -- All sexually active women should be screened ... infections: chlamydia and gonorrhea, according to new recommendations ... The task force noted this recommendation includes ... age and pregnant women. Most women with ... a result, many infections go undetected. If left ...
(Date:9/22/2014)... Steven Reinberg HealthDay Reporter ... are urging that all children aged 6 months and older ... Academy of Pediatrics updated their influenza vaccine recommendations to advise ... vaccine to build immunity. The AAP also wants parents of ... the nasal spray vaccine instead of the flu shot if ...
(Date:9/22/2014)... Hamilton, ON (September 22, 2014) McMaster scientists have ... a new class of antibiotics. , Although dozens ... looked at how a certain part of bacteria are ... stopping it. , The discovery is important as ... is making the cures for infections ineffective. The World ...
(Date:9/22/2014)... September 22, 2014 Quincy Bioscience, ... United States, promotes National Self-Improvement Month ... all individuals should have access to self-improvement resources, ... , The demand for products that preserve health ... ever before. For over six years, Quincy Bioscience ...
Breaking Medicine News(10 mins):Health News:Federal Court Sets Trial Date for Boston Scientific Vaginal Mesh Cases in Florida, the Rottenstein Law Group LLP Reports 2Health News:Screen Women for Chlamydia, Gonorrhea, Experts Say 2Health News:Pediatricians Urge Flu Vaccine for All Kids 6 Months and Older 2Health News:Pediatricians Urge Flu Vaccine for All Kids 6 Months and Older 3Health News:Quincy Bioscience Promotes National Self-Improvement Month 2
... Dramatically Cut Largest Source of Deadly Diesel Pollution in State ... 12 The California Air Resources Board today approved two ... of diesel pollution in the state and are the first ... Defense Fund (EDF). The Air Resource Board estimates that the ...
... national partners in effort to raise $5 million , ... National partners from the 17th annual Halloween Promotion benefiting ... celebrate raising more than $2.4 million to help the hospital ... , Companies represented at today,s recognition ceremony ...
... cells may make them more resilient during real attack, experts ... have long known that the creation of a "mini ... flow to arteries -- can actually reduce the damage from ... how that protective effect occurs, according to research from the ...
... PartsSource, the nation,s leading,supplier of replacement medical repair parts for ... in Ohio by the Case Western Reserve,University Weatherhead ... placed 14th on this year,s list with a growth rate ... eligible. , "The Weatherhead ...
... to bad treatment decisions, study shows , , FRIDAY, ... receive about the risk of their breast cancer ... whether to get chemotherapy more difficult, a new ... patients a bar chart, based on a standard ...
... A new report from the Institute of Medicine, THE ... ADMINISTRATION, examines why a commitment to global health is ... light of the current economic situation. The report ... goals the incoming administration should strive to meet, and ...
Cached Medicine News:Health News:California Rules to Cut Diesel Truck Pollution Called Most Sweeping in U.S. 2Health News:More Than $2.4 Million Raised by National Halloween Promotion Partners to Help St. Jude Fight Childhood Cancer 2Health News:Research Explains Benefit of 'Mini Heart Attack' 2Health News:Risk Info for Breast Cancer Patients Too Confusing 2
(Date:9/22/2014)... PLYMOUTH MEETING, Pa. , Sept. 22, 2014 ... ) announced today it has initiated a phase ... The trial will evaluate the safety, tolerability, and ... type 6 (HPV-6), which causes most aerodigestive cancers. ... tongue, nose, throat, vocal cords, and parts of ...
(Date:9/22/2014)... and NEW YORK , Sept. ... ACCP), has signed an exclusive, global license agreement ... and commercialization of its proprietary plasma fractionation process. ... team and its intention to strategically refocus and ... its plans to pursue a national listing for ...
(Date:9/22/2014)... Pa. , Sept. 22, 2014 ... a specialty biopharmaceutical company, today announced that its ... unsolicited, non-binding and conditional proposal from Endo International ... financial and legal advisors, has unanimously determined it ... of its existing merger agreement with QLT Inc. ...
Breaking Medicine Technology:Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers 2Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers 3Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers 4Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 2Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 3Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 4Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 5Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 6Auxilium Provides Transaction Update 2Auxilium Provides Transaction Update 3Auxilium Provides Transaction Update 4Auxilium Provides Transaction Update 5Auxilium Provides Transaction Update 6
... SAN DIEGO, Feb. 6, 2012 Amylin Pharmaceuticals, Inc. (Nasdaq: ... quarter and year ended December 31, 2011. ... $164.9 million, which included net product sales of $160.9 million. ... 2011 was $17.6 million, compared to a non-GAAP operating income ...
... Feb. 6, 2012  Genomic Health, Inc. (Nasdaq: GHDX ... with the goal of improving the quality of diagnosis, communication ... with common and rare genetic conditions.   The subsidiary is expected ... first commercial service in 2013.  The new venture will be ...
Cached Medicine Technology:Amylin Pharmaceuticals Reports Fourth Quarter and Full Year 2011 Financial Results 2Amylin Pharmaceuticals Reports Fourth Quarter and Full Year 2011 Financial Results 3Amylin Pharmaceuticals Reports Fourth Quarter and Full Year 2011 Financial Results 4Amylin Pharmaceuticals Reports Fourth Quarter and Full Year 2011 Financial Results 5Amylin Pharmaceuticals Reports Fourth Quarter and Full Year 2011 Financial Results 6Amylin Pharmaceuticals Reports Fourth Quarter and Full Year 2011 Financial Results 7Amylin Pharmaceuticals Reports Fourth Quarter and Full Year 2011 Financial Results 8Amylin Pharmaceuticals Reports Fourth Quarter and Full Year 2011 Financial Results 9Genomic Health Announces Formation of New Genetics Subsidiary 2Genomic Health Announces Formation of New Genetics Subsidiary 3Genomic Health Announces Formation of New Genetics Subsidiary 4
... with a curvature of 12 ... of the retina. Instrument shaft ... For cutting membranes adherent to ... for cutting in small folds ...
Claes Shielded Retinotomy Scissors, Curved Vertical...
Claes Shielded Retinotomy Scissors, Vertical...
Indirect hemagglutination assay (IHA) for the detection and semi-quantitation of human antibodies to the bacteria of the genus Leptospira. Each kit contains test cells, control cells, and positive an...
Medicine Products: